These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 29472156)

  • 1. Novel biomarkers in bladder cancer.
    Cheng ML; Iyer G
    Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Making urothelial carcinomas less immune to immunotherapy.
    Ramos JD; Yu EY
    Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
    Raggi D; Necchi A; Giannatempo P
    Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular limitations of biomarker research in bladder cancer.
    Vlachostergios PJ; Faltas BM
    World J Urol; 2019 May; 37(5):837-848. PubMed ID: 30171455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
    Dhariwal R; Pindoria N; Dasgupta P; Khan MS
    BJU Int; 2019 Feb; 123(2):203-207. PubMed ID: 29974606
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in the treatment of advanced bladder cancer.
    Godwin JL; Hoffman-Censits J; Plimack E
    Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
    Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
    Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
    Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
    Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?
    Rassy E; Assi T; Kattan J
    Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.
    Kim J; Kwiatkowski D; McConkey DJ; Meeks JJ; Freeman SS; Bellmunt J; Getz G; Lerner SP
    Eur Urol; 2019 Jun; 75(6):961-964. PubMed ID: 30851984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma.
    Balar AV
    Oncology (Williston Park); 2019 Apr; 33(4):132-6. PubMed ID: 30990565
    [No Abstract]   [Full Text] [Related]  

  • 18. Biomarkers for immunotherapy in urological cancers.
    Gust KM; Resch I; D'Andrea D
    Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
    Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
    World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
    Roviello G; Catalano M; Nobili S; Santi R; Mini E; Nesi G
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.